Cost-effectiveness analysis of sugemalimab combined with chemotherapy as first-line treatment for advanced gastric cancer

Cost-effectiveness analysis of sugemalimab combined with chemotherapy as first-line treatment for advanced gastric cancer

ObjectiveBased on findings from the GEMSTONE-303 trial, the sugemalimab plus capecitabine and oxaliplatin regimen showed superior clinical efficacy compared to chemotherapy alone in advanced gastric cancer patients. This economic evaluation study assesses the cost-effectiveness of sugemalimab combin...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lian Tang, LongXun Zhu, ShaoQing Zhan, Yong Chen, Pan-Feng Feng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Public Health
Subjects:	sugemalimab first-line treatment advanced gastric cancer partitioned survival model cost-effectiveness analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fpubh.2025.1620663/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effective analysis of sugemalimab plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 CPS ≥5
by: Yalan Zhang, et al.
Published: (2025-08-01)

Sugemalimab plus chemotherapy vs. chemotherapy for treatment of Chinese patients with esophageal squamous cell carcinoma: a cost effectiveness analysis to inform decision making
by: Qiuping Chen, et al.
Published: (2025-06-01)

THE ROLE OF ADJUVANT CHEMOTHERAPY IN THE TREATMENT OF LOCALLY ADVANCED GASTRIC CANCER
by: A. A. Bobryshev, et al.
Published: (2021-03-01)

Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China
by: Chunyan Yan, et al.
Published: (2025-03-01)

Efficacy, safety, and biomarker analysis of first-line immune checkpoint inhibitors with chemotherapy versus chemotherapy for advanced gastric cancer: a multicenter, retrospective cohort study
by: Xue Zhang, et al.
Published: (2024-12-01)

A case of advanced gastric cancer achieved a pathological complete response by chemotherapy
by: Kazuhiro Tada, et al.
Published: (2017-05-01)

Impact of nutrition risk index, prognostic nutritional index and skeletal muscle index on early myelosuppression of first-line chemotherapy in stage IV gastric cancer patients
by: Juan Wei, et al.
Published: (2024-12-01)

Efficacy and safety of programmed cell death protein-1 inhibitor for first-line therapy of advanced gastric or gastroesophageal junction cancer: a network meta-analysis
by: Yunnan Zhang, et al.
Published: (2025-04-01)

Correction: Cannabidiol inhibits invasion and metastasis in colorectal cancer cells by reversing epithelial–mesenchymal transition through the Wnt/β-catenin signaling pathway
by: PanFeng Feng, et al.
Published: (2025-07-01)

Incorporation of liver chemistry score in predicting survival of liver‐involved advanced gastric cancer patients who received palliative chemotherapy
by: Ying Feng, et al.
Published: (2023-02-01)

Cost-effectiveness analysis of tislelizumab plus chemotherapy as first-line treatment for HER2-negative advanced gastric or gastro-oesophageal junction adenocarcinoma
by: Liangliang Zou, et al.
Published: (2025-05-01)

Cadonilimab in combination with chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a cost-effectiveness analysis
by: Zuojuan Xiang, et al.
Published: (2025-07-01)

Cost-effectiveness analysis of first-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma
by: Zhifeng Zhou, et al.
Published: (2025-05-01)

Efficacy and safety of apatinib in the second-line treatment of advanced gastric cancer
by: GUO Mengya, CHEN Yue, PENG Weiwei, SHA Huanhuan, FANG Ying, ZHOU Guoren
Published: (2025-01-01)

Real-world efficacy and safety of anlotinib combined with chemotherapy for advanced pancreatic cancer: a retrospective study
by: Zhiyong Li, et al.
Published: (2025-12-01)

Impact of pathological complete response on survival in gastric cancer after neoadjuvant chemotherapy: a propensity score matching analysis
by: Yonghe Chen, et al.
Published: (2025-01-01)

Anlotinib plus camrelizumab and chemotherapy as first-line treatment in patients with advanced esophageal squamous cell carcinoma
by: Mingfang Xu, et al.
Published: (2025-07-01)

Clinical and morphological response to neoadjuvant chemotherapy followed by chemoradiotherapy in a patient with locally advanced gastric cancer: a case report
by: V. Yu. Skoropad, et al.
Published: (2023-06-01)

Comparison of outcomes between surgery and non-surgery after conversion therapy for advanced gastric cancer with unresectable factors: a systematic review and meta-analysis
by: Jiaheng Wu, et al.
Published: (2025-05-01)

Complete remission in PD-L1 high expression advanced gastric cancer patient with PD-L1 immunotherapy and chemotherapy integration treatment strategy: a case report
by: Xiaopeng Yu, et al.
Published: (2025-05-01)

Changing landscape of first-line treatment for locally advanced or metastatic urothelial carcinoma: the progression from platinum-based chemotherapy to platinum-free therapy
by: Zengguang Liu, et al.
Published: (2025-06-01)

Successful conversion surgery for stage IV gastric cancer with liver metastases after second-line chemotherapy with ramucirumab and paclitaxel: a case report
by: Kosuke Fukuda, et al.
Published: (2022-04-01)

Case Report: Endoscopic submucosal tunneling dissection using a golden knife for a giant gastric cancer lesion: a case report and literature review
by: Pan Wu, et al.
Published: (2025-05-01)

ACCELERATED HYPERFRACTIONATED RADIOTHERAPY IN THE TREATMENT FOR INOPERABLE, LOCALLY ADVANCED GASTRIC CANSER
by: S. S. Litinskiy, et al.
Published: (2016-02-01)

First-Line Therapy for Patients with Advanced Hodgkin’s Lymphoma: Efficacy and Toxicity of Intensive ЕАСОРР-14 Program (NN Blokhin National Medical Cancer Research Center Data)
by: EA Demina, et al.
Published: (2017-10-01)

Efficacy and safety of programmed death-1 inhibitors combined with chemotherapy in patients with advanced gastric cancer
by: Xiaofei Cheng, et al.
Published: (2025-08-01)

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for extensive-stage small cell lung cancer from the perspective of the healthcare system in China
by: Feng Chen, et al.
Published: (2025-05-01)

The impact of delayed adjuvant chemotherapy on survival in gastric cancer patients with and without preoperative chemotherapy
by: Masataka Shimonosono, et al.
Published: (2025-07-01)

Efficacy and safety of oxaliplatin-based chemotherapy as first-line treatment in elderly patients with metastatic colorectal cancer: a meta-analysis
by: Shaoqing Fan, et al.
Published: (2025-04-01)

Modern means of endoscopic diagnosis for dysplastic changes of gastric lining
by: M. I. Bykov, et al.
Published: (2019-02-01)

Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer
by: Longfeng Zhang, et al.
Published: (2025-07-01)

The expression and prognostic predictive value of PD-L2 in patients undergoing radical gastric cancer surgery
by: Xiuping Zhang, et al.
Published: (2025-12-01)

Adjuvant chemotherapy for stage II and III gastric adenocarcinoma: A retrospective analysis with long-term follow-up
by: Hsiu-Tzu Wang, et al.
Published: (2025-04-01)

Analysis of ICIs alone or in combination rechallenged outcomes after progression from first-line ICIs plus chemotherapy in patients with advanced non-small cell lung cancer
by: Guisen Yin, et al.
Published: (2025-01-01)

Predictive role of inflammatory markers for the efficacy of first-line immunotherapy plus chemotherapy in advanced gastric cancer
by: Chenming Zhong, et al.
Published: (2025-04-01)

PD‐1/PD‐L1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone as First‐Line Therapy for Patients With Unfavorable Cancer of Unknown Primary: A Multicenter, Retrospective Cohort Study
by: Riqing Huang, et al.
Published: (2025-03-01)

Timing of postoperative chemotherapy and prognosis in neoadjuvant-treated gastric cancer patients: a multicenter real-world cohort study
by: Hua-Long Zheng, et al.
Published: (2025-12-01)

A prognostic prediction model for advanced gastric cancer based on Ki67
by: NIU Linjun*，LI Xinzhong，LYU Yongjian
Published: (2025-07-01)

Toripalimab plus chemotherapy versus chemotherapy as first-line therapy for extensive-stage small cell lung cancer: a cost-effectiveness analysis
by: Longfeng Zhang, et al.
Published: (2025-07-01)

Factors influencing the timing of second-line therapy for the treatment of advanced hepatocellular carcinoma: a systematic review and meta-analysis
by: Xiaoze Zhang, et al.
Published: (2025-06-01)